A Phase 3 interventional study of 13vPnC in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 24 sites in Japan. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-08.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after 3-dose infant series (at 7 months of age)
Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the 3-Dose Infant Series
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one mone month after 3-dose infant series (at 7 months of age)
Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the Toddler Dose
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after the toddler dose (at 12 - 15 months of age)
Geometric Mean Antibody Concentration (GMC) in 13vPnC Group Relative After the Toddler Dose
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
Time frame: one month after the toddler dose (at 12-15 months of age)
Percentage of Participants Reporting Pre-Specified Local Reactions
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
Time frame: Within 7 days after each dose
Percentage of Participants Reporting Pre-Specified Systemic Events
Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
Time frame: Within 7 days after each dose
Participants were recruited in Japan from September 2007 to February 2008.
| Milestone | 13vPnC |
|---|---|
| Started | 193 |
| Vaccinated dose 1 | 193 |
| Vaccinated dose 2 | 190 |
| Vaccinated dose 3 | 190 |
| Completed | 188 |
| Not completed | 5 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Adverse event | 1 |
| Milestone | 13vPnC |
|---|---|
| Started | 188 |
| Completed | 185 |
| Not completed | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Adverse event | 2 |
| Milestone | 13vPnC |
|---|---|
| Started | 185 |
| Completed | 184 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC After Infant Series |
|---|---|
| Common Serotypes - Serotype 4 | 100.0 (97.9 to 100.0) |
| Common Serotypes - Serotype 6B | 98.3 (95.1 to 99.6) |
| Common Serotypes - Serotype 9V | 100.0 (97.9 to 100.0) |
| Common Serotypes - Serotype 14 | 100.0 (97.9 to 100.0) |
| Common Serotypes - Serotype 18C | 100.0 (97.9 to 100.0) |
| Common Serotypes - Serotype 19F | 97.2 (93.5 to 99.1) |
| Common Serotypes - Serotype 23F | 97.7 (94.3 to 99.4) |
| Additional Serotypes - Serotype 1 | 100.0 (97.9 to 100.0) |
| Additional Serotypes - Serotype 3 | 100.0 (97.9 to 100.0) |
| Additional Serotypes - Serotype 5 | 100.0 (97.9 to 100.0) |
| Additional Serotypes - Serotype 6A | 100.0 (97.9 to 100.0) |
| Additional Serotypes - Serotype 7F | 100.0 (97.9 to 100.0) |
| Additional Serotypes - Serotype 19A | 100.0 (97.9 to 100.0) |
Local reactions were collected using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 13vPnC Dose 2 | 13vPnC Dose 3 | 13vPnC Toddler Dose |
|---|---|---|---|---|
| Tenderness - Any (n=165,156,147,143) | 13.3 | 19.9 | 14.3 | 18.2 |
| Tenderness - Significant (n=160,152,143,132) | 0.6 | 0.0 | 0.0 | 0.0 |
| Swelling - Any (n=176,173,165,163) | 47.2 | 53.8 | 53.9 | 57.1 |
| Swelling - Mild (n=174,171,163,154) | 46.0 | 49.1 | 50.3 | 44.2 |
| Swelling - Moderate (n=167,164,150,151) | 14.4 | 28.7 | 29.3 | 36.4 |
| Swelling - Severe (n=160,153,143,132) | 0.0 | 1.3 | 0.7 | 2.3 |
| Redness - Any (n=186,180,171,166) | 74.2 | 74.4 | 67.8 | 68.1 |
| Redness - Mild (n=183,179,162,156) | 68.3 | 64.8 | 55.6 | 53.8 |
| Redness - Moderate (n=170,168,157,155) | 24.7 | 43.5 | 38.9 | 40.6 |
| Redness - Severe (n=160,153,143,132) | 0.0 | 1.3 | 0.7 | 1.5 |
Systemic events (fever ≥ 37.5 degrees Celsius \[C\], fever ≥ 38 C but ≤ 39 C, fever \>39 C but ≤ 40 C, fever \> 40 C, decreased appetite, irritability, increased sleep, decreased sleep, hives, use of medication to treat symptoms, and use of medication to prevent symptoms) were reported using an electronic diary. Participants may be represented in more than 1 category.
| percentage of participants | 13vPnC Dose 1 | 13vPnC Dose 2 | 13vPnC Dose 3 | 13vPnC Toddler Dose |
|---|---|---|---|---|
| Fever ≥37.5°C (n=170,163,154,150) | 32.9 | 33.1 | 40.3 | 50.7 |
| Fever ≥38°C but ≤39°C (n=163,156,146,137) | 6.7 | 12.2 | 10.3 | 20.4 |
| Fever >39°C but ≤40°C (n=161,153,143,133) | 1.2 | 2.6 | 2.8 | 5.3 |
| Fever >40°C (n=160,152,143,132) | 0.0 | 0.7 | 0.0 | 0.0 |
| Decreased appetite (n=163,158,144,138) | 11.7 | 16.5 | 9.7 | 18.1 |
| Irritability (n=170,166,149,140) | 30.6 | 36.1 | 23.5 | 26.4 |
| Increased sleep (n=175,160,153,139) | 40.6 | 29.4 | 22.2 | 24.5 |
| Decreased sleep (n=169,160,145,138) | 21.3 | 23.1 | 15.9 | 12.3 |
| Hives (n=160,152,143,132) | 1.3 | 1.3 | 0.7 | 0.0 |
| Medication to treat symptoms (n=160,153,145,135) | 1.9 | 6.5 | 5.5 | 8.1 |
| Medication to prevent symptoms (n=160,153,144,134) | 0.6 | 3.3 | 2.1 | 3.0 |
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC After Infant Series |
|---|---|
| Common Serotypes - Serotype 4 | 6.76 (6.02 to 7.59) |
| Common Serotypes - Serotype 6B | 4.77 (4.07 to 5.59) |
| Common Serotypes - Serotype 9V | 3.39 (3.03 to 3.78) |
| Common Serotypes - Serotype 14 | 14.69 (13.26 to 16.26) |
| Common Serotypes - Serotype 18C | 3.68 (3.27 to 4.14) |
| Common Serotypes - Serotype 19F | 5.71 (4.90 to 6.65) |
| Common Serotypes - Serotype 23F | 2.57 (2.21 to 3.00) |
| Additional Serotypes - Serotype 1 | 5.11 (4.48 to 5.82) |
| Additional Serotypes - Serotype 3 | 2.87 (2.55 to 3.24) |
| Additional Serotypes - Serotype 5 | 3.85 (3.42 to 4.33) |
| Additional Serotypes - Serotype 6A | 3.77 (3.35 to 4.25) |
| Additional Serotypes - Serotype 7F | 5.78 (5.19 to 6.45) |
| Additional Serotypes - Serotype 19A | 6.97 (6.25 to 7.77) |
Percentages of participants achieving World Health Organization (WHO) predefined antibody threshold ≥ 0.35 μg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| percentage of participants | 13vPnC After Toddler Dose |
|---|---|
| Common Serotypes - Serotype 4 | 100 (97.9 to 100) |
| Common Serotypes - Serotype 6B | 100 (97.9 to 100) |
| Common Serotypes - Serotype 9V | 100 (97.9 to 100) |
| Common Serotypes - Serotype 14 | 100 (97.9 to 100) |
| Common Serotypes - Serotype 18C | 100 (97.9 to 100) |
| Common Serotypes - Serotype 19F | 98.9 (96 to 99.9) |
| Common Serotypes - Serotype 23F | 98.9 (96 to 99.9) |
| Additional Serotypes - Serotype 1 | 100 (97.9 to 100) |
| Additional Serotypes - Serotype 3 | 99.4 (96.9 to 100) |
| Additional Serotypes - Serotype 5 | 100 (97.9 to 100) |
| Additional Serotypes - Serotype 6A | 100 (97.9 to 100) |
| Additional Serotypes - Serotype 7F | 100 (97.9 to 100) |
| Additional Serotypes - Serotype 19A | 100 (97.9 to 100) |
GMC as measured by enzyme-linked immunosorbent assay (ELISA) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.
| μg/mL | 13vPnC After Toddler Dose |
|---|---|
| Common Serotypes - Serotype 4 | 9.70 (8.43 to 11.17) |
| Common Serotypes - Serotype 6B | 14.61 (12.52 to 17.05) |
| Common Serotypes - Serotype 9V | 4.49 (4.00 to 5.06) |
| Common Serotypes - Serotype 14 | 16.33 (14.49 to 18.41) |
| Common Serotypes - Serotype 18C | 6.09 (5.34 to 6.95) |
| Common Serotypes - Serotype 19F | 12.20 (10.37 to 14.35) |
| Common Serotypes - Serotype 23F | 6.55 (5.53 to 7.75) |
| Additional Serotypes - Serotype 1 | 9.85 (8.62 to 11.27) |
| Additional Serotypes - Serotype 3 | 2.06 (1.83 to 2.32) |
| Additional Serotypes - Serotype 5 | 7.31 (6.52 to 8.20) |
| Additional Serotypes - Serotype 6A | 11.03 (9.69 to 12.55) |
| Additional Serotypes - Serotype 7F | 8.31 (7.39 to 9.35) |
| Additional Serotypes - Serotype 19A | 15.97 (14.07 to 18.13) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC Infant Series | — | 9/193 (4.7%) | 192/193 (99.5%) |
| 13vPnC Post-Infant Series | — | 14/193 (7.3%) | 19/193 (9.8%) |
| 13vPnC Toddler Dose | — | 1/185 (0.5%) | 171/185 (92.4%) |
| Event | 13vPnC Infant Series | 13vPnC Post-Infant Series | 13vPnC Toddler Dose |
|---|---|---|---|
| BronchiolitisInfections and infestations | 2/193 | 0/193 | 0/185 |
| Febrile convulsionNervous system disorders | 0/193 | 2/193 | 0/185 |
| PertussisInfections and infestations | 0/193 | 2/193 | 0/185 |
| PneumoniaInfections and infestations | 0/193 | 2/193 | 0/185 |
| Pneumonia respiratory syncytial viralInfections and infestations | 2/193 | 1/193 | 0/185 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/193 | 1/193 | 1/185 |
| Adenovirus infectionInfections and infestations | 1/193 | 0/193 | 0/185 |
| BronchitisInfections and infestations | 0/193 | 1/193 | 0/185 |
| Cellulitis staphylococcalInfections and infestations | 1/193 | 0/193 | 0/185 |
| Enteritis infectiousInfections and infestations | 0/193 | 1/193 | 0/185 |
| Event | 13vPnC Infant Series | 13vPnC Post-Infant Series | 13vPnC Toddler Dose |
|---|---|---|---|
| Injection site erythemaGeneral disorders | 163/193 | 0/193 | 115/185 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 134/180 | 0/193 | 0/185 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 138/186 | 0/193 | 113/166 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 125/183 | 0/193 | 84/156 |
| Erythema (Any)Skin and subcutaneous tissue disorders | 116/171 | 0/193 | 0/185 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 116/179 | 0/193 | 0/185 |
| Injection site swellingGeneral disorders | 121/193 | 0/193 | 94/185 |
| Induration (Any)Skin and subcutaneous tissue disorders | 83/176 | 0/193 | 93/163 |
| PyrexiaGeneral disorders | 108/193 | 0/193 | 80/185 |
| Erythema (Mild)Skin and subcutaneous tissue disorders | 90/162 | 0/193 | 0/185 |
| Age Continuous(months) | 13vPnC |
|---|---|
| Mean | 3.7 ± 1.5 |
| Sex: Female, Male(Participants) | 13vPnC |
|---|---|
| Female | 93 |
| Male | 100 |
The record gives a start of Sep 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →